A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
Status:
Not yet recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to
evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in
participants diagnosed with early Alzheimer's disease.